Anti-Ovarian Cancer Compound Library

Anti-Ovarian Cancer Compound Library
SKU
MEXHY-L173-100
Packaging Unit
100 μl
Manufacturer
MedChemExpress

Availability: loading...
Price is loading...
Description: Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.
MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.
MCE Anti-Ovarian Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1835 compounds supplied in 10 mM solution, 46 compounds supplied in 2 mM solution and 2 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:
  • A unique collection of 1883 with identified and potential anti-ovarian cancer activity for high throughput screening (HTS) and high content screening (HCS).
  • The library contains compounds targeting the PARP, ATM/ATR, VEGFR, HIF/HIF Prolyl-Hydroxylase, etc.
  • A useful tool for the discovery of anti-ovarian cancer compounds.
  • Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
  • Structurally diverse, bioactive, and cell permeable.
  • More detailed compound information with structure, IC50, and other chemical & biological data.
  • High purity and quality validated by NMR and LC/MS.
  • All compounds are in stock and continuously updated.


Formulation: A collection of 1883 bioactive compounds related to ovarian cancer supplied as pre-dissolved Solutions or Solid.Solution:1835 compounds supplied in 10 mM solution,46 compounds supplied in 2 mM solution,2 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
More Information
SKU MEXHY-L173-100
Manufacturer MedChemExpress
Manufacturer SKU HY-L173-100
Green Labware No
Package Unit 100 μl
Quantity Unit STK
Product information (PDF)
×
MSDS (PDF)
×